[Music] It's big. It's bold. And it's not to be underestimated.The future of our health is going to be transformed. And it's going to affect you, me, and everyone. For the best part of two decades, I've covered the greatest innovation on Earth.I've been to space agencies, tasted future food, hung out with a load of robots, even been sort of turned into one. It involved an exoskeleton, and been invited to the moon. But this is the ultimate human story, and it needs to be told.Powering it is AI. Not alone, of ...

Core Viewpoint - Illumina, Inc. will announce its third quarter 2025 financial results on October 30, 2025, followed by a conference call to discuss these results with analysts and investors [1]. Group 1: Conference Call Details - The conference call will take place at 1:30 PM Pacific Time (4:30 PM Eastern Time) on October 30, 2025 [1]. - Interested parties can access the live webcast through Illumina's Investor Info section or via a direct link [1]. - Participants are encouraged to join the call at least ten minutes early to ensure timely connection [1]. Group 2: Replay Information - A replay of the conference call will be available on Illumina's website for at least 30 days following the event [2]. Group 3: Company Overview - Illumina is a global leader in DNA sequencing and array-based technologies, focusing on improving human health through genomic advancements [3]. - The company's products serve various markets, including life sciences, oncology, reproductive health, and agriculture [3].

[μουσική] [χειροκρότημα] [χειροκρότημα] Καλησπέρα σας. Έχετε κάνει ποτέ μια εξέταση και φοβηθήκατε να δείτε το αποτέλεσμα Μπορεί να ήτανε κάτι απλό, μια γενική αίματος ή κάτι λίγο πιο σοβαρό, μια μικρή βιοψία. Εκείνη στιγμή που ο φόβος να μάθεις ξεπερνάει την ανάγκη να ξέρεις.Τώρα φανταστείτε πως η εξέταση αυτή δεν αφορά το παρόν, αλλά το μέλλον σας. Πώς θα νιώθατε αν ξέρετε ότι έχετε για παράδειγμα 60% αυξημένο κίνδυνο να εμφανίσετε καρδιακιακή νόσο ή 40% μεγαλύτερη πιθανότητα για αλzχάμε στα 58 σας θα θέλ ...

Genome sequencing company G&DX surpassing a hundred million dollars in revenue for the first time in its most recent quarter. A lot more than that though. They also talked about how they're raising their guidance for the fiscal year.They flipped to a profit from a loss in the previous quarter and saw some pretty impressive growth particularly when it came to exo and genome testing sales which were up by 69%. The company screens for and diagnoses rare diseases in newborns. And joining us right now is Katheri ...